A referral to secondary care is necessary when there is a history of breast cancer in the patient’s paternal family. This is because breast cancer may not be detectable during a routine breast examination, and waiting for a screening appointment could result in a delayed diagnosis. It is important to note that a review in one year may also lead to a delay in diagnosis, as the patient is at a high risk for familial breast cancer.

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme. Mammograms are provided every three years, and women over 70 years are encouraged to make their own appointments. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually.

For those with familial breast cancer, NICE guidelines recommend referral if there is a family history of breast cancer with any of the following: diagnosis before age 40, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, sarcoma in a relative under 45 years, glioma or childhood adrenal cortical carcinomas, complicated patterns of multiple cancers at a young age, or paternal history of breast cancer with two or more relatives on the father’s side. Women at increased risk due to family history may be offered screening at a younger age. Referral to a breast clinic is recommended for those with a first-degree relative diagnosed with breast cancer before age 40, a first-degree male relative with breast cancer, a first-degree relative with bilateral breast cancer before age 50, two first-degree relatives or one first-degree and one second-degree relative with breast cancer, or a first- or second-degree relative with breast and ovarian cancer.

For a newly diagnosed patient of black African or African-Caribbean origin with hypertension, adding a calcium channel blocker (CCB) such as nifedipine is recommended as the first-line treatment. This is because ACE inhibitors and ARBs are less effective in patients of these ethnicities. Lifestyle advice alone is not sufficient if the patient’s average blood pressure reading on ambulatory monitoring is greater than 150/95 mmHg. Ramipril is not the first-line option for this patient population, and Losartan is a second-line option after CCBs.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Ulipristal, also known as EllaOne, is a form of emergency hormonal contraception that can be taken within 120 hours after engaging in unprotected sexual intercourse.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Drugs that can cause sensitivity to light

Photosensitivity is a condition where the skin becomes more sensitive to light, resulting in rashes, blisters, and other skin irritations. Certain drugs can cause photosensitivity, making it important to be aware of the medications that can cause this condition. Some of the drugs that can cause photosensitivity include thiazides, tetracyclines, sulphonamides, ciprofloxacin, amiodarone, NSAIDs like piroxicam, psoralens, and sulphonylureas.

Thiazides are a type of diuretic that can cause photosensitivity, while tetracyclines, sulphonamides, and ciprofloxacin are antibiotics that can also cause this condition. Amiodarone is a medication used to treat heart rhythm problems, but it can also cause photosensitivity. NSAIDs like piroxicam are pain relievers that can cause photosensitivity, while psoralens are used to treat skin conditions like psoriasis and can also cause photosensitivity. Sulphonylureas are medications used to treat diabetes that can cause photosensitivity as well.

It is important to note that not everyone who takes these medications will experience photosensitivity, but it is still important to be aware of the potential side effects.

Scarring alopecia can be caused by various factors such as trauma/burns, radiotherapy, discoid lupus, tinea capitis, and lichen planus. However, out of these options, lichen planus is the only cause that leads to scarring alopecia. The remaining causes, including alopecia areata, carbimazole, trichotillomania, and telogen effluvium, result in non-scarring alopecia.

Input:
Alopecia may be divided into scarring (destruction of hair follicle) and non-scarring (preservation of hair follicle). Scarring alopecia can be caused by trauma, burns, radiotherapy, lichen planus, discoid lupus, and untreated tinea capitis. Non-scarring alopecia can be caused by male-pattern baldness, drugs such as cytotoxic drugs, carbimazole, heparin, oral contraceptive pill, and colchicine, nutritional deficiencies such as iron and zinc deficiency, autoimmune conditions such as alopecia areata, telogen effluvium, hair loss following a stressful period such as surgery, and trichotillomania.

Output:
– Alopecia can be categorized into scarring and non-scarring types.
– Scarring alopecia is caused by trauma, burns, radiotherapy, lichen planus, discoid lupus, and untreated tinea capitis.
– Non-scarring alopecia is caused by male-pattern baldness, drugs such as cytotoxic drugs, carbimazole, heparin, oral contraceptive pill, and colchicine, nutritional deficiencies such as iron and zinc deficiency, autoimmune conditions such as alopecia areata, telogen effluvium, hair loss following a stressful period such as surgery, and trichotillomania.

Antibiotic therapy is the appropriate course of action to reduce mortality in cirrhotic patients experiencing gastrointestinal bleeding. Prophylactic antibiotics, particularly quinolones, should be administered alongside terlipressin for individuals suspected of having variceal bleeding. The use of cimetidine is not recommended for acute treatment before endoscopy, but it may be used as a preventative measure for mild acid reflux symptoms. Octreotide is sometimes used as an alternative to terlipressin, but studies indicate that it is less effective in reducing mortality. Propranolol is utilized as a prophylactic measure to decrease the incidence of variceal bleeding.

Variceal haemorrhage is a serious condition that requires prompt management. The initial treatment involves resuscitation of the patient before endoscopy. Correcting clotting with FFP and vitamin K is important, as is the use of vasoactive agents such as terlipressin or octreotide. Prophylactic IV antibiotics are also recommended to reduce mortality in patients with liver cirrhosis. Endoscopic variceal band ligation is the preferred method of treatment, and the use of a Sengstaken-Blakemore tube or Transjugular Intrahepatic Portosystemic Shunt (TIPSS) may be necessary if bleeding cannot be controlled. Propranolol and EVL are effective in preventing rebleeding and mortality, and are recommended by NICE guidelines. Proton pump inhibitor cover is given to prevent EVL-induced ulceration.

Measles: Symptoms, Complications, and Prevention

Measles is a highly contagious viral infection that can lead to serious respiratory complications such as pneumonia, bronchiolitis, and bronchiectasis. While it does not cause recurrent pneumothoraces, severe infection from prolonged exposure to infected siblings in overcrowded households can be fatal.

Koplik’s spots, small red spots with bluish-white centers, are a characteristic late sign of measles infection that may appear on the mucous membranes of the mouth 1-2 days before the rash appears.

Contrary to popular belief, lifelong immunity is often established after natural infection with measles. This is also the mechanism by which the MMR vaccine prevents measles infection in later life.

Measles can also lead to corneal ulceration, especially in cases of vitamin A deficiency. High-dose oral vitamin A supplementation is recommended for all children with measles in developing countries to prevent this complication.

Overall, prevention through vaccination is the best way to avoid the serious complications of measles.

In the case of a pregnant woman who is not immune to rubella, it is recommended to offer the MMR vaccination after giving birth. Rubella can cause severe harm to the developing foetus, especially during the first 8-10 weeks of pregnancy. Although congenital rubella syndrome is now rare due to widespread MMR vaccination, there has been a resurgence of measles, mumps, and rubella outbreaks in developed countries due to the anti-vaccination movement. The woman should avoid contact with individuals who may have rubella and cannot receive the vaccine while pregnant. Referral to an obstetrician is not necessary at this time since the woman is asymptomatic and in good health. The MMR vaccine should not be administered at 20 weeks of pregnancy, and if the woman is not immune, it should be offered postnatally. If there is a suspicion of rubella based on the woman’s clinical presentation, the local Health Protection Team should be notified, but this is not necessary in this case since there is no suspicion.

Rubella and Pregnancy: Risks, Features, Diagnosis, and Management

Rubella, also known as German measles, is a viral infection caused by the togavirus. Thanks to the introduction of the MMR vaccine, it is now rare. However, if contracted during pregnancy, there is a risk of congenital rubella syndrome, which can cause serious harm to the fetus. It is important to note that the incubation period is 14-21 days, and individuals are infectious from 7 days before symptoms appear to 4 days after the onset of the rash.

The risk of damage to the fetus is highest in the first 8-10 weeks of pregnancy, with a risk as high as 90%. However, damage is rare after 16 weeks. Features of congenital rubella syndrome include sensorineural deafness, congenital cataracts, congenital heart disease (e.g. patent ductus arteriosus), growth retardation, hepatosplenomegaly, purpuric skin lesions, ‘salt and pepper’ chorioretinitis, microphthalmia, and cerebral palsy.

If a suspected case of rubella in pregnancy arises, it should be discussed immediately with the local Health Protection Unit (HPU) as type/timing of investigations may vary. IgM antibodies are raised in women recently exposed to the virus. It should be noted that it is very difficult to distinguish rubella from parvovirus B19 clinically. Therefore, it is important to also check parvovirus B19 serology as there is a 30% risk of transplacental infection, with a 5-10% risk of fetal loss.

If a woman is tested at any point and no immunity is demonstrated, they should be advised to keep away from people who might have rubella. Non-immune mothers should be offered the MMR vaccination in the post-natal period. However, MMR vaccines should not be administered to women known to be pregnant or attempting to become pregnant.

Immediate percutaneous coronary intervention with aspirin, clopidogrel, and IV heparin is recommended.

Myocardial infarction, specifically ST-elevation myocardial infarction (STEMI), can be managed using evidence-based approaches. Patients without contraindications should be given aspirin and a P2Y12-receptor antagonist, with ticagrelor being preferred over clopidogrel due to improved outcomes despite slightly higher bleeding rates. Unfractionated heparin is typically given to patients undergoing percutaneous coronary intervention (PCI), but low-molecular weight heparin can also be used. Oxygen therapy should not be routinely administered, but supplemental oxygen can be given to patients with oxygen saturation levels below 94% or those with chronic obstructive pulmonary disease at risk of hypercapnic respiratory failure.

Primary PCI is the preferred treatment for STEMI, but it may not be available in all centers. Thrombolysis can be performed in patients without access to primary PCI, with tissue plasminogen activator (tPA) offering clear mortality benefits over streptokinase. Tenecteplase is easier to administer and has non-inferior efficacy to alteplase with a similar adverse effect profile. An ECG should be performed 90 minutes following thrombolysis to assess whether there has been a greater than 50% resolution in the ST elevation. If there has not been adequate resolution, rescue PCI is superior to repeat thrombolysis. For patients successfully treated with thrombolysis, PCI has been shown to be beneficial, but the optimal timing is still being investigated.

For patients with diabetes mellitus, NICE recommends using a dose-adjusted insulin infusion with regular monitoring of blood glucose levels to keep glucose below 11.0 mmol/l. Intensive insulin therapy regimes are not recommended routinely.

It is possible that this individual has developed toxic megacolon, which is characterized by a transverse colon diameter exceeding 6 cm and accompanying symptoms of systemic distress. Treatment for toxic megacolon typically involves intensive medical intervention for a period of 24-72 hours. If there is no improvement in the patient’s condition during this time, a colectomy may be necessary.

Understanding Ulcerative Colitis Flares

Ulcerative colitis is a chronic inflammatory bowel disease that can cause flares or periods of worsening symptoms. While most flares occur without a clear trigger, there are several factors that are often associated with them. These include stress, certain medications such as NSAIDs and antibiotics, and even quitting smoking.

Flares of ulcerative colitis can be classified as mild, moderate, or severe based on the frequency and severity of symptoms. Mild flares may involve fewer than four stools a day with or without blood, while moderate flares may include four to six stools a day with minimal systemic disturbance. Severe flares, on the other hand, may involve more than six stools a day containing blood, as well as evidence of systemic disturbance such as fever, tachycardia, abdominal tenderness, distension, reduced bowel sounds, anemia, and hypoalbuminemia.

Patients with evidence of severe disease should be admitted to the hospital for close monitoring and treatment. Understanding the triggers and symptoms of ulcerative colitis flares can help patients manage their condition and seek appropriate medical care when necessary.